一名年轻成人产 Verona 整合子编码金属β-内酰胺酶（VIM）的铜绿假单胞菌肾盂肾炎：病例报告
Verona Integron-Encoded Metallo-β-Lactamase (VIM)-Producing Pseudomonas aeruginosa Pyelonephritis in a Young Adult: A Case Report.
作者信息
De Freitas Gerson
机构信息
Internal Medicine, St. Luke's Hospital, Bethlehem, USA.
出版信息
Cureus. 2025 Feb 13;17(2):e78932. doi: 10.7759/cureus.78932. eCollection 2025 Feb.
Abstract
We report a case of pyelonephritis caused by Verona integron-encoded metallo-β-lactamase (VIM)-producing in a 23-year-old female who presented from the community with flank pain and fever, and whose urine culture confirmed the presence of VIM-positive . Treatment with ceftazidime-avibactam resulted in a favorable outcome. This case highlights the emerging threat of carbapenem-resistant (CRPA) infections and the effectiveness of ceftazidime-avibactam.
摘要
我们报告了一例由产 Verona 整合子编码金属β-内酰胺酶（VIM）的细菌引起的肾盂肾炎病例，患者为一名 23 岁女性，因社区获得性胁腹痛和发热就诊，其尿培养证实存在 VIM 阳性细菌。使用头孢他啶-阿维巴坦治疗取得了良好效果。该病例凸显了耐碳青霉烯类肺炎克雷伯菌（CRPA）感染的新威胁以及头孢他啶-阿维巴坦的有效性。
相似文献
1
Verona Integron-Encoded Metallo-β-Lactamase (VIM)-Producing Pseudomonas aeruginosa Pyelonephritis in a Young Adult: A Case Report.
Cureus. 2025 Feb 13;17(2):e78932. doi: 10.7759/cureus.78932. eCollection 2025 Feb.
2
Difficult-to-treat (DTR) harboring Verona-Integron metallo-β-lactamase (): infection management and molecular analysis.
Antimicrob Agents Chemother. 2024 May 2;68(5):e0147423. doi: 10.1128/aac.01474-23. Epub 2024 Apr 11.
3
ARGONAUT-III and -V: susceptibility of carbapenem-resistant and multidrug-resistant to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime.
Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0075124. doi: 10.1128/aac.00751-24. Epub 2024 Aug 12.
4
High prevalence of carbapenem-resistant and identification of a novel VIM-type metallo-β-lactamase, VIM-92, in clinical isolates from northern China.
Front Microbiol. 2025 Feb 26;16:1543509. doi: 10.3389/fmicb.2025.1543509. eCollection 2025.
5
Mortality associated with carbapenem-susceptible and Verona Integron-encoded Metallo-β-lactamase-positive Pseudomonas aeruginosa bacteremia.
Antimicrob Resist Infect Control. 2020 Feb 3;9(1):25. doi: 10.1186/s13756-020-0682-4.
6
Containment of a Verona Integron-Encoded Metallo-Beta-Lactamase-Producing Outbreak Associated With an Acute Care Hospital Sink-Tennessee, 2018-2020.
Open Forum Infect Dis. 2023 Apr 11;10(5):ofad194. doi: 10.1093/ofid/ofad194. eCollection 2023 May.
7
First report of NDM-1-producing Pseudomonas aeruginosa in Egypt.
Int J Infect Dis. 2014 Dec;29:80-1. doi: 10.1016/j.ijid.2014.07.008. Epub 2014 Oct 24.
8
Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France.
Antimicrob Agents Chemother. 2000 Apr;44(4):891-7. doi: 10.1128/AAC.44.4.891-897.2000.
9
PBP-3 directed therapy in VIM-producing Pseudomonas aeruginosa creates bacterial transformers, persisters in disguise.
Int J Antimicrob Agents. 2024 Sep;64(3):107260. doi: 10.1016/j.ijantimicag.2024.107260. Epub 2024 Jun 28.
10
Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
Acta Microbiol Immunol Hung. 2020 Mar 26;67(1):61-65. doi: 10.1556/030.2020.01152.
本文引用的文献
1
Profile of outer membrane proteins of carbapenem-resistant Gram-negative bacilli in Ghana.
BMC Res Notes. 2025 Feb 1;18(1):49. doi: 10.1186/s13104-024-07070-6.
2
Five-year VIM-producing Pseudomonas aeruginosa outbreak in four Belgian ICUs, an investigation report (2019-2023).
Am J Infect Control. 2024 Dec;52(12):1425-1431. doi: 10.1016/j.ajic.2024.08.022. Epub 2024 Aug 31.
3
Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria.
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0075122. doi: 10.1128/aac.00751-22. Epub 2022 Sep 14.
4
Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by .
Antibiotics (Basel). 2021 Sep 18;10(9):1126. doi: 10.3390/antibiotics10091126.
5
Outbreak of Pseudomonas aeruginosa producing VIM carbapenemase in an intensive care unit and its termination by implementation of waterless patient care.
Crit Care. 2021 Aug 19;25(1):301. doi: 10.1186/s13054-021-03726-y.
6
Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline.
Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.00397-20.
7
Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections.
Clin Microbiol Rev. 2019 Aug 28;32(4). doi: 10.1128/CMR.00031-19. Print 2019 Sep 18.
8
Metallo-beta-Lactamase-producing Pseudomonas aeruginosa in Iran: a systematic review and meta-analysis.
Infez Med. 2018 Sep 1;26(3):216-225.
9
Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.
Int J Antimicrob Agents. 2018 Aug;52(2):287-292. doi: 10.1016/j.ijantimicag.2018.04.001. Epub 2018 Apr 11.
10
VIM-positive in a large tertiary care hospital: matched case-control studies and a network analysis.
Antimicrob Resist Infect Control. 2018 Feb 27;7:32. doi: 10.1186/s13756-018-0325-1. eCollection 2018.
Zotero 插件